Does the media prefer TNYA or GYRE?

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 1 mentions for Gyre Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.26 beat Gyre Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor TNYA or RGNX?

In the previous week, REGENXBIO had 8 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.26 beat REGENXBIO's score of 0.21 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral REGENXBIO 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, MNPR or TNYA?

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Monopar Therapeutics N/A N/A -$13.72M -$1.90 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is MNPR or TNYA more profitable?

Monopar Therapeutics' return on equity of -12.84% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Monopar Therapeutics N/A -12.84% -12.57% Tenaya Therapeutics N/A -80.56% -65.21%

Does the media refer more to MNPR or TNYA?

In the previous week, Monopar Therapeutics had 4 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Tenaya Therapeutics. Monopar Therapeutics' average media sentiment score of 0.65 beat Tenaya Therapeutics' score of 0.26 indicating that Monopar Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monopar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, AURA or TNYA?

Aura Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aura Biosciences N/A N/A -$106.19M -$1.74 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is AURA or TNYA more profitable?

Aura Biosciences' return on equity of -78.12% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Tenaya Therapeutics N/A -80.56% -65.21%

Which has better earnings and valuation, CADL or TNYA?

Candel Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Candel Therapeutics N/A N/A -$38.18M -$0.98 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is CADL or TNYA more profitable?

Candel Therapeutics' return on equity of -60.42% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Candel Therapeutics N/A -60.42% -41.33% Tenaya Therapeutics N/A -80.56% -65.21%

Does the media favor CADL or TNYA?

In the previous week, Candel Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Candel Therapeutics and 2 mentions for Tenaya Therapeutics. Candel Therapeutics' average media sentiment score of 0.45 beat Tenaya Therapeutics' score of 0.26 indicating that Candel Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Candel Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenaya Therapeutics (TNYA) Competitors

$0.82 +0.01 (+0.78%)

Closing price 04:00 PM Eastern

Extended Trading

$0.82 0.00 (-0.19%)

As of 04:35 PM Eastern

Compare

TNYA vs. GYRE, RGNX, MNPR, AURA, and CADL

Should you buy Tenaya Therapeutics stock or one of its competitors? MarketBeat compares Tenaya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenaya Therapeutics include Gyre Therapeutics (GYRE), REGENXBIO (RGNX), Monopar Therapeutics (MNPR), Aura Biosciences (AURA), and Candel Therapeutics (CADL). These companies are all part of the "pharmaceutical products" industry.

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

Gyre Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Gyre Therapeutics	$117.05M	5.77	$5.03M	-$0.09	N/A

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 1 mentions for Gyre Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.26 beat Gyre Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics currently has a consensus target price of $4.00, suggesting a potential upside of 385.08%. Gyre Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 180.53%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Tenaya Therapeutics is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Tenaya Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Tenaya Therapeutics has a beta of 2.83, indicating that its share price is 183% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market.

Summary

Tenaya Therapeutics beats Gyre Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to REGENXBIO?

Tenaya Therapeutics (NASDAQ:TNYA) and REGENXBIO (NASDAQ:RGNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, profitability, institutional ownership, media sentiment, earnings and analyst recommendations.

Tenaya Therapeutics has a beta of 2.83, meaning that its share price is 183% more volatile than the broader market. Comparatively, REGENXBIO has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Tenaya Therapeutics currently has a consensus target price of $4.00, indicating a potential upside of 385.08%. REGENXBIO has a consensus target price of $23.82, indicating a potential upside of 130.35%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Tenaya Therapeutics is more favorable than REGENXBIO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
REGENXBIO	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.62

In the previous week, REGENXBIO had 8 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 10 mentions for REGENXBIO and 2 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.26 beat REGENXBIO's score of 0.21 indicating that Tenaya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
REGENXBIO	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has higher earnings, but lower revenue than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
REGENXBIO	$87.82M	6.09	-$193.88M	-$5.60	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 88.1% of REGENXBIO shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 14.2% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tenaya Therapeutics has a net margin of 0.00% compared to REGENXBIO's net margin of -330.23%. Tenaya Therapeutics' return on equity of -80.56% beat REGENXBIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
REGENXBIO	-330.23%	-232.50%	-61.02%

Summary

Tenaya Therapeutics beats REGENXBIO on 11 of the 16 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Monopar Therapeutics?

Monopar Therapeutics (NASDAQ:MNPR) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

Monopar Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monopar Therapeutics	N/A	N/A	-$13.72M	-$1.90	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

In the previous week, Monopar Therapeutics had 4 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 6 mentions for Monopar Therapeutics and 2 mentions for Tenaya Therapeutics. Monopar Therapeutics' average media sentiment score of 0.65 beat Tenaya Therapeutics' score of 0.26 indicating that Monopar Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monopar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

1.8% of Monopar Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 9.7% of Monopar Therapeutics shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Monopar Therapeutics' return on equity of -12.84% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monopar Therapeutics	N/A	-12.84%	-12.57%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Monopar Therapeutics currently has a consensus target price of $108.75, suggesting a potential downside of 4.24%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 385.08%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Monopar Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monopar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	3 Strong Buy rating(s)	3.07
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Monopar Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, meaning that its stock price is 183% more volatile than the broader market.

Summary

Monopar Therapeutics beats Tenaya Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Aura Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 1.9% of Aura Biosciences shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Aura Biosciences currently has a consensus price target of $20.50, suggesting a potential upside of 191.61%. Tenaya Therapeutics has a consensus price target of $4.00, suggesting a potential upside of 385.08%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Aura Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Aura Biosciences. MarketBeat recorded 2 mentions for Tenaya Therapeutics and 0 mentions for Aura Biosciences. Tenaya Therapeutics' average media sentiment score of 0.26 beat Aura Biosciences' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aura Biosciences	Neutral
Tenaya Therapeutics	Neutral

Aura Biosciences has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market.

Aura Biosciences' return on equity of -78.12% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats Aura Biosciences on 11 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Candel Therapeutics?

Candel Therapeutics (NASDAQ:CADL) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations and valuation.

Candel Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Candel Therapeutics	N/A	N/A	-$38.18M	-$0.98	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

In the previous week, Candel Therapeutics had 2 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 4 mentions for Candel Therapeutics and 2 mentions for Tenaya Therapeutics. Candel Therapeutics' average media sentiment score of 0.45 beat Tenaya Therapeutics' score of 0.26 indicating that Candel Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Candel Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Candel Therapeutics presently has a consensus target price of $18.57, indicating a potential upside of 81.72%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 385.08%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Candel Therapeutics' return on equity of -60.42% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Candel Therapeutics	N/A	-60.42%	-41.33%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Candel Therapeutics has a beta of -0.52, indicating that its stock price is 152% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.83, indicating that its stock price is 183% more volatile than the broader market.

13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 14.3% of Candel Therapeutics shares are owned by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Candel Therapeutics and Tenaya Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$178.94M	$3.66B	$6.82B	$12.42B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-1.75	20.80	27.00	24.20
Price / Sales	N/A	322.97	519.38	94.43
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.45	8.17	10.67	6.26
Net Income	-$90.60M	$23.81M	$3.60B	$331.76M
7 Day Performance	-4.63%	-1.12%	-0.32%	-1.10%
1 Month Performance	12.87%	2.64%	1.88%	-1.26%
1 Year Performance	-3.74%	45.50%	25.50%	18.84%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	2.4844 of 5 stars	$0.82 +0.8%	$4.00 +385.1%	-6.7%	$178.94M	N/A	N/A	110	Gap Down
GYRE Gyre Therapeutics	1.6859 of 5 stars	$6.34 -2.8%	$17.00 +168.1%	-18.4%	$726.91M	$116.59M	N/A	40	Positive News
RGNX REGENXBIO	3.6379 of 5 stars	$12.75 -8.6%	$23.82 +86.8%	+26.5%	$721.18M	$170.44M	N/A	370	Gap Down
MNPR Monopar Therapeutics	1.311 of 5 stars	$103.33 -3.1%	$108.75 +5.2%	+127.8%	$714.12M	N/A	N/A	10	News Coverage
AURA Aura Biosciences	1.5884 of 5 stars	$7.00 +2.3%	$20.50 +192.9%	+1.6%	$707.16M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. GYRE, RGNX, MNPR, AURA, and CADL

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Summary

How does Tenaya Therapeutics compare to REGENXBIO?

Summary

How does Tenaya Therapeutics compare to Monopar Therapeutics?

Summary

How does Tenaya Therapeutics compare to Aura Biosciences?

Summary

How does Tenaya Therapeutics compare to Candel Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. GYRE, RGNX, MNPR, AURA, and CADL

How does Tenaya Therapeutics compare to Gyre Therapeutics?

Which has preferable earnings and valuation, TNYA or GYRE?

Does the media prefer TNYA or GYRE?

Do analysts recommend TNYA or GYRE?

Do institutionals & insiders have more ownership in TNYA or GYRE?

Is TNYA or GYRE more profitable?

Which has more volatility & risk, TNYA or GYRE?

Summary

How does Tenaya Therapeutics compare to REGENXBIO?

Which has more volatility & risk, TNYA or RGNX?

Do analysts rate TNYA or RGNX?

Does the media favor TNYA or RGNX?

Which has higher earnings & valuation, TNYA or RGNX?

Do institutionals and insiders believe in TNYA or RGNX?

Is TNYA or RGNX more profitable?

Summary

How does Tenaya Therapeutics compare to Monopar Therapeutics?

Which has better valuation and earnings, MNPR or TNYA?

Does the media refer more to MNPR or TNYA?

Do institutionals and insiders hold more shares of MNPR or TNYA?

Is MNPR or TNYA more profitable?

Do analysts prefer MNPR or TNYA?

Which has more risk and volatility, MNPR or TNYA?

Summary

How does Tenaya Therapeutics compare to Aura Biosciences?

Which has better earnings & valuation, AURA or TNYA?

Do insiders and institutionals have more ownership in AURA or TNYA?

Do analysts prefer AURA or TNYA?

Does the media favor AURA or TNYA?

Which has more risk & volatility, AURA or TNYA?

Is AURA or TNYA more profitable?

Summary

How does Tenaya Therapeutics compare to Candel Therapeutics?

Which has better earnings and valuation, CADL or TNYA?

Does the media favor CADL or TNYA?

Do analysts prefer CADL or TNYA?

Is CADL or TNYA more profitable?

Which has more volatility & risk, CADL or TNYA?

Do institutionals & insiders believe in CADL or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools